According to uniQure's latest financial reports the company has a price-to-book ratio of 1.55.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2024-12-31 | N/A | -100% |
2023-12-31 | 1.56 | -30.09% |
2022-12-31 | 2.23 | 38.59% |
2021-12-31 | 1.61 | -75.59% |
2020-12-31 | 6.59 | -32.02% |
2019-12-31 | 9.70 | 61.78% |
2018-12-31 | 5.99 | -11.24% |
2017-12-31 | 6.75 | 205.23% |
2016-12-31 | 2.21 | -29.67% |
2015-12-31 | 3.15 | -38.47% |
2014-12-31 | 5.11 | |
2013-12-31 | N/A | |
2012-12-31 | N/A |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
Amgen AMGN | 32.2 | 1,976.66% | ๐บ๐ธ USA |
Sanofi SNY | 1.46 | -5.53% | ๐ซ๐ท France |
Sangamo Therapeutics
SGMO | 2.12 | 36.61% | ๐บ๐ธ USA |
bluebird bio
BLUE | 0.7781 | -49.74% | ๐บ๐ธ USA |
BioMarin Pharmaceutical BMRN | 2.81 | 81.36% | ๐บ๐ธ USA |
Avidity Biosciences RNA | 3.11 | 101.17% | ๐บ๐ธ USA |